top of page
Why Pharma's Capital Expansion Boom Is Creating a CQV Supercycle - And Why CORE Is the Partner Built for This Moment
Why Pharma's Capital Expansion Boom Is Creating a CQV Supercycle Biopharma is entering one of the most consequential transformation cycles in its history. Across the globe, companies are building new manufacturing facilities at unprecedented speed—facilities designed not merely to expand capacity, but to keep pace with fundamental shifts in science, global supply chain dynamics, and rising regulatory expectations. This surge of investment in biologics, mRNA, and cell and gene
3 min read
The Hidden Cost of Validation Gaps and Overly Complex Programs: Why Hiring the Right Experts Matters
The Hidden Cost of Validation Gaps and Overly Complex Programs Yet, too often, organizations underestimate the ripple effects that...
2 min read
Best Practices for Remediation in Life Sciences: Avoiding Common Pitfalls
In the life sciences industry, remediation is a critical process for addressing and correcting non-compliance issues, quality defects,...
3 min read
Trends in 21 CFR Compliance: What’s Changing in 2024?
As the life sciences industry continues to advance, so too do the regulatory frameworks that govern it. The Code of Federal Regulations...
3 min read
The Importance of Commissioning & Qualifications (CQV) in Life Sciences Projects
In the rapidly evolving life sciences industry, the success of any project—be it the development of a new pharmaceutical product, the...
3 min read
bottom of page